Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00939146 · ClinicalTrials.gov registry record · NA

Outlook: An Intervention to Improve Quality of Life in Serious Illness

A NA study of Heart Failure and Neoplasms, sponsored by Duke University.

Completed
Registry status
NA
Development phase
154
Enrollment target
1
Study location

NCT00939146 is a NA study of Heart Failure and Neoplasms that has completed, run by Duke University. The registered enrollment target is 154 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00939146, a NA study of Heart Failure and Neoplasms, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
154 participants
Enrollment target
1
Study location

Study Summary

This study will demonstrate whether an end-of-life preparation and completion intervention reduces anxiety, depression, pain and other symptoms and improves functional status, spiritual well-being, and quality of life. If effective, the intervention offers a brief, inexpensive, and transportable non-physician treatment method for improving the experience of individuals in the latter stages of life-limiting illness.

Interventions

  • OTHER Outlook Attention Control
  • OTHER Outlook Intervention

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 154 participants
Start Date 2010-02
Est. Completion 2013-09
Phase NA

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT00939146

The ClinicalTrials.gov registry entry for NCT00939146 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (92% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Outlook Attention Control is the first listed.

NCT00939146 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT00939146 about?

NCT00939146 is a clinical study titled "Outlook: An Intervention to Improve Quality of Life in Serious Illness". This study will demonstrate whether an end-of-life preparation and completion intervention reduces anxiety, depression, pain and other symptoms and improves functional status, spiritual well-being, and quality of life. If effective, the intervention offers a brief, inexpensive, and transportable non...

What is the current status of trial NCT00939146?

This trial is currently completed. It is a NA study. The enrollment target is 154 participants. The study started on 2010-02. Estimated completion is 2013-09.

What conditions does trial NCT00939146 study?

This clinical trial studies the following conditions: Heart Failure, Neoplasms, Pulmonary Disease, Chronic Obstructive, Renal Disease.

What interventions are being tested in trial NCT00939146?

The interventions under investigation include: Outlook Attention Control (OTHER), Outlook Intervention (OTHER).

Who is sponsoring clinical trial NCT00939146?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00939146 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.